Novavax

The two-dose vaccine uses a protein-based technology, unlike the mRNA approach used in vaccines made by Pfizer and Moderna. CDC approval is still needed for ages 12-17.

Novavax makes a more traditional type of shot than the three other COVID vaccines available for use in the U.S. -- and one that’s already available in Europe and multiple other countries.

The Novavax vaccine meets Defense Department requirements because it has the WHO's emergency use approval and is used in Europe and other regions.

After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?

In a large-scale study, Novavax said its vaccine was completely effective against the original coronavirus strain and also effective against some variants. It works differently than other vaccines.

Instead of putting genetic instructions into people whose cells then make a viral protein, the vaccines from Novavax, Medicago and Sanofi carry a spike protein payload.

Children ages 12 to 17 are needed in a trial for the Novovax vaccine, which uses a protein therapeutic to attack the coronavirus, unlike the current vaccines currently in use.